• Alkaline Phosphatase Substrate Kit: Evidence Scope

  2026-10-12

  The Alkaline Phosphatase (AP) Substrate Test Kit, SKU K4151, is documented by APExBIO as a BCIP/NBT chromogenic product intended for visualizing alkaline phosphatase enzyme activity. Available evidence supports its stated identity and conceptual scope, but no matched peer-reviewed study or independent performance dataset was provided.

• Cy5 NHS ester(Et): Documented Product Scope

  2026-10-12

  Cy5 NHS ester(Et) (SKU A8769) is described by APExBIO as a water-soluble fluorescent dye reagent for conceptual labeling of primary amines in proteins, peptides, and other biomolecules. The available evidence is limited to supplier documentation; no matched research paper was provided to establish performance, mechanism beyond the stated reactive-group description, or application-specific outcomes.

• Tumor Exosomal ENPP1 and cGAMP Signaling

  2026-10-11

  A source-grounded overview of research linking ENPP1-bearing tumor exosomes with extracellular 2'3'-cGAMP degradation, reduced STING-mediated innate immune response, and altered immune-cell infiltration, with emphasis on evidence strength and applicability limits.

• Remdesivir (GS-5734): Evidence and Limits

  2026-10-10

  Remdesivir (GS-5734) is an antiviral nucleoside analogue prodrug studied against coronaviruses, filoviruses and other RNA viruses. This overview compares mechanistic, cell-based, animal and clinical evidence, while clarifying why coronavirus and Ebola findings cannot be directly extrapolated to Nipah virus.

• Indometacin Sodium: From COX Biology to Translation

  2026-10-09

  Indometacin Sodium is best understood as both a canonical cyclooxygenase inhibitor and a hypothesis-generating tool for studying inflammatory stroma. Evidence from human pancreatic stellate cells supports a COX-2-linked reduction in activation-associated phenotypes, while translational researchers should treat broader pathway claims, clinical relevance, and disease-modifying potential as questions requiring independent validation.

• X-Gal: Molecular Biology Context and Olfactory Evidence

  2026-10-09

  X-Gal is a chromogenic β-galactosidase substrate central to blue-white colony screening and reporter assays. The supplied 2024 olfaction study provides a separate, mechanistic context involving iRhom2, ADAM17, olfactory receptors, and activity-dependent transcription. This overview compares what X-Gal can conceptually report with what the olfactory study actually measured, while defining evidence limits and applicability boundaries.

• Sulforaphane, Oxidative Stress, and NLRP3 in Colitis

  2026-10-08

  A 2024 study connected sulforaphane-mediated reduction of reactive oxygen species with suppression of NLRP3 inflammasome signaling in mouse colitis and macrophage-like cells. Its main contribution is mechanistic integration across animal and cellular models, while its preclinical design limits direct conclusions about human ulcerative colitis treatment.

• 5-(N,N-dimethyl)-Amiloride in Translational Research

  2026-10-08

  A thought-leadership analysis of 5-(N,N-dimethyl)-Amiloride hydrochloride as a mechanistic probe for intracellular pH regulation, ion transport, endothelial injury, and cardiac research. The article connects NHE biology with moesin-based sepsis research while distinguishing preclinical signals from clinically established evidence.

• Sorafenib and the Next Frontier in Liver Cancer Biology

  2026-10-07

  A mechanistic and translational perspective on Sorafenib (BAY-43-9006), its value as a cancer biology research tool, and how recent findings on cholesterol-driven mitophagy broaden research questions in hepatocellular carcinoma.

• Gut Dysbiosis and α-Synuclein Pathology in Parkinson’s

  2026-10-07

  This mouse study connects rotenone-associated gut microbiota dysbiosis with intestinal barrier disruption, inflammation, C/EBPβ/AEP signaling, α-synuclein pathology, and motor deficits. Its microbiota-depletion and fecal-transfer comparisons provide intervention-based evidence that the gut microbiome can modify pathology in this Parkinson’s disease model, while leaving important questions about human relevance unresolved.

• RISOTTO Trial: Risedronate in RA-Related GIO

  2026-10-06

  The RISOTTO study evaluated sodium risedronate in 95 patients with rheumatoid arthritis and glucocorticoid-induced osteoporosis in a multicentre, randomized, double-blind, placebo-controlled trial. Risedronate produced a significantly larger six-month increase in lumbar spine bone mineral density, while effects at the femoral neck and total hip were not significant and safety findings require longer follow-up.

• SMYD2 Inhibition in Cisplatin-Related Renal Fibrosis

  2026-10-06

  A 2023 study investigated whether pharmacological inhibition of SMYD2 could reduce cisplatin-associated renal fibrosis and inflammation. Using an in vivo injury model and cultured tubular epithelial cells, the authors linked SMYD2 inhibition with improved renal injury readouts, reduced fibrotic and inflammatory markers, and altered Smad3, STAT3, and Smad7 signaling.

• Docking-Based Vitamin Repurposing for COVID-19

  2026-10-05

  The 2022 Journal of Molecular Modeling study by Eskandari used virtual screening, molecular docking, and molecular dynamics simulations to examine vitamin-related compounds against SARS-CoV-2 3CLpro and the spike receptor-binding domain. Its findings nominate several compounds for further antiviral therapeutics research, but the computational evidence does not establish biochemical inhibition, antiviral activity, or clinical benefit.

• Berberine Hydrochloride and the Metabolic–Inflammation Axis

  2026-10-05

  Berberine hydrochloride is best understood as a translational research probe at the intersection of energy sensing, lipid metabolism, cell survival, and inflammation. This article connects its reported AMPK and LDLR-related biology with findings from a 2025 acute kidney injury study that identifies oxidized self-DNA, STING, NLRP3, and A20–NEK7 signaling as an inflammatory network, while clarifying what remains hypothesis rather than established mechanism.

• 2'3'-cGAMP in STING-Mediated Innate Immunity

  2026-10-04

  A source-grounded overview of 2'3'-cGAMP and its role as a direct STING pathway agonist, with emphasis on conceptual applications, the REC8 innate-immunity study, evidence strength, and limits on translating pathway findings to antiviral or immunotherapy claims.

8022 records 1/535 page Next 12345 下5页 Last page